Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

by Zacks Equity Research

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 24.29% and 6.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $324.62 in the latest trading session, marking a -1.08% move from the prior day.

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

by Zacks Equity Research

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

by Zacks Equity Research

The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

by Zacks Equity Research

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Lilly (LLY) Stock Riding on Pipeline Developments This Year

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

by Zacks Equity Research

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

by Zacks Equity Research

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

by Zacks Equity Research

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

Ekta Bagri headshot

3 Biotech Stocks Poised to Gain in the Second Half of 2021

by Ekta Bagri

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

by Zacks Equity Research

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

Cassava (SAVA) Stock Up on Alzheimer's Candidate Update

by Zacks Equity Research

Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.

Here's Why Prothena (PRTA) Stock Is Up So Far This Month

by Zacks Equity Research

Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

by Zacks Equity Research

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

Sweta Jaiswal, FRM headshot

Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight

by Sweta Jaiswal, FRM

The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.